Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors

Introduction: Somatic evolution of the cancer genome resulting in genetically different subclones is thought to be involved in the development of treatment resistance but might also offer new therapeutic opportunities in metastatic breast cancer. No data are available if clonal evolution differs in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncology research and treatment 2022-05, Vol.45 (5), p.248-253
Hauptverfasser:	Decker, Thomas, Bichler, Matthias, Birtel, Andrea, Fischer, Gerhard, Geiger, Kathrin, Gaenger, Stella, Nonnenbroich, Christoph, Dechow, Tobias, Muendlein, Axel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Circulating Tumor DNA - genetics Clonal Evolution Cyclin-Dependent Kinase 4 - genetics Cyclin-Dependent Kinase 4 - therapeutic use Cyclin-Dependent Kinase 6 - antagonists & inhibitors Female Humans Receptor, ErbB-2 - genetics Research Article Triple Negative Breast Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!